TCR2 Therapeutics TCRR Stock
TCR2 Therapeutics Price Chart
TCR2 Therapeutics TCRR Financial and Trading Overview
| TCR2 Therapeutics stock price | 1.48 USD |
| Previous Close | 1.48 USD |
| Open | 1.58 USD |
| Bid | 1.49 USD x 1000 |
| Ask | 1.63 USD x 1800 |
| Day's Range | 1.48 - 1.48 USD |
| 52 Week Range | 0.82 - 3.88 USD |
| Volume | 3.75M USD |
| Avg. Volume | 328.86K USD |
| Market Cap | 58.11M USD |
| Beta (5Y Monthly) | 1.93322 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.43 USD |
TCRR Valuation Measures
| Enterprise Value | -46224616 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.60162604 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.5731991 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.358 |
Trading Information
TCR2 Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.93322 |
| 52-Week Change | -40.32% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.88 USD |
| 52 Week Low | 0.82 USD |
| 50-Day Moving Average | 1.69 USD |
| 200-Day Moving Average | 1.56 USD |
TCRR Share Statistics
| Avg. Volume (3 month) | 328.86K USD |
| Avg. Daily Volume (10-Days) | 702.89K USD |
| Shares Outstanding | 39.26M |
| Float | 26.75M |
| Short Ratio | 1.29 |
| % Held by Insiders | 1.49% |
| % Held by Institutions | 54.31% |
| Shares Short | 360.9K |
| Short % of Float | 1.15% |
| Short % of Shares Outstanding | 0.91% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -34.72% |
| Return on Equity (ttm) | -91.46% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -128953000 USD |
| Net Income Avi to Common (ttm) | -163099008 USD |
| Diluted EPS (ttm) | -4.2 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 110.31M USD |
| Total Cash Per Share (mrq) | 2.81 USD |
| Total Debt (mrq) | 5.98M USD |
| Total Debt/Equity (mrq) | 5.9 USD |
| Current Ratio (mrq) | 2.959 |
| Book Value Per Share (mrq) | 2.582 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -110337000 USD |
| Levered Free Cash Flow (ttm) | -69133504 USD |
Profile of TCR2 Therapeutics
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 100 Binney Street |
| ZIP | 02142 |
| Phone | (617) 949-5200 |
| Website | https://www.tcr2.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 58 |
TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. Its lead product candidate is gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin-expressing solid tumors, which is in Phase 1/2 clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma and acute myeloid leukemia. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Q&A For TCR2 Therapeutics Stock
What is a current TCRR stock price?
TCR2 Therapeutics TCRR stock price today per share is 1.48 USD.
How to purchase TCR2 Therapeutics stock?
You can buy TCRR shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for TCR2 Therapeutics?
The stock symbol or ticker of TCR2 Therapeutics is TCRR.
Which industry does the TCR2 Therapeutics company belong to?
The TCR2 Therapeutics industry is Biotechnology.
How many shares does TCR2 Therapeutics have in circulation?
The max supply of TCR2 Therapeutics shares is 39.26M.
What is TCR2 Therapeutics Price to Earnings Ratio (PE Ratio)?
TCR2 Therapeutics PE Ratio is 0.00000000 now.
What was TCR2 Therapeutics earnings per share over the trailing 12 months (TTM)?
TCR2 Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the TCR2 Therapeutics company belong to?
The TCR2 Therapeutics sector is Healthcare.
TCR2 Therapeutics TCRR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}